Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 5, 2011, Pages 2082-2087

  Hu, Chuhong ^a   Cela, Racel G ^b   Suzuki, Masataka ^b   Lee, Brendan ^a,b   Lipshutz, Gerald S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Coagulation; Immune response

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; GENE EXPRESSION; GENE THERAPY; HEMOPHILIA A; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; DRUG TOLERANCE; FACTOR VIII; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS; INFANT, NEWBORN; MICE; MICE, KNOCKOUT;

ADENOVIRIDAE; ANIMALIA; MIRIDAE; MUS;

EID: 79952122629     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015571108     Document Type: Article

References (57)

1. Wight J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 9:418-435. (Pubitemid 36874391)
2. Lollar P (2004) Pathogenic antibodies to coagulation factors. Part one: Factor VIII and factor IX. J Thromb Haemost 2:1082-1095.
3. Cunningham SC, Dane AP, Spinoulas A, Logan GJ, Alexander IE (2008) Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther 16:1081-1088. (Pubitemid 351737073)
4. Sabatino DE, et al. (2007) Persistent expression of hF.IX after tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. Mol Ther 15:1677-1685. (Pubitemid 47289012)
5. Kyosen SO, et al. (2010) Neonatal gene transfer using lentiviral vector for murine Pompe disease: Long-term expression and glycogen reduction. Gene Ther 17:521-530.
6. Pacak CA, et al. (2006) Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99:e3-e9. (Pubitemid 44255502)
7. Waddington SN, et al. (2004) Fetal and neonatal gene therapy: Benefits and pitfalls. Gene Ther 11(Suppl 1):S92-S97. (Pubitemid 39359453)
8. Ponder KP (2007) Immunology of neonatal gene transfer. Curr Gene Ther 7:403-410.
9. Takahashi M, et al. (1996) Long term correction of bilirubin-UDP- glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J Biol Chem271:26536-26542. (Pubitemid 26359052)
10. Xu L, et al. (2002) Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of betaglucuronidase in mucopolysaccharidosis VII dogs. Mol Ther 5:141-153. (Pubitemid 34144830)
11. Xu L, et al. (2002) Evaluation of pathological manifestations of disease in mucopolysaccharidosisVIImice after neonatal hepatic genetherapy.Mol Ther 6:745-758.
12. Ponder KP, et al. (2002) Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 99:13102-13107.
13. Mah C, et al. (2005) Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 12:1405-1409. (Pubitemid 43090390)
14. Foust KD, et al. (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28:271-274.
15. Hacein-Bey-Abina S, et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118:3132-3142.
16. Hacein-Bey-Abina S, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419. (Pubitemid 37296260)
17. Ginn SL, et al. (2010) Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 18:965-976.
18. Cerullo V, et al. (2007) Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors. Mol Ther 15:2080-2087. (Pubitemid 350148922)
19. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H (1992) Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232:25-32.
20. Astermark J, et al. (1999) Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 105:1109-1113. (Pubitemid 29309124)
21. Ljung R (2002) Paediatric care of the child with haemophilia. Haemophilia 8:178-182.
22. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group (2003) Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS Study Group. Blood 102:2358-2363. (Pubitemid 37193570)
23. Schwaab R, et al. (1995) Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 74:1402-1406. (Pubitemid 26018063)
24. Goodeve A (2003) The incidence of inhibitor development according to specific mutations - and treatment? Blood Coagul Fibrinolysis 14(Suppl 1):S17-S21.
25. Oldenburg J, et al. (2004) Environmental and genetic factors influencing inhibitor development. Semin Hematol 41(1, Suppl 1):82-88. (Pubitemid 38182722)
26. Schröder J, El-Maarri O, Schwaab R, Müller CR, Oldenburg J (2006) Factor VIII intron-1 inversion: Frequency and inhibitor prevalence. J Thromb Haemost 4:1141-1143.
27. Viel KR, et al. (2009) Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 360:1618-1627.
28. Lorenzo JI, López A, Altisent C, Aznar JA (2001) Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 113:600-603. (Pubitemid 32524377)
29. Goudemand J, et al.; FVIII-LFB and Recombinant FVIII study groups (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107:46-51.
30. Aledort LM, Dimichele DM (1998) Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 4:68.
31. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS; Kogenate Previously Untreated Patient Study Group (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 328:453-459.
32. Qian J, Borovok M, Bi L, Kazazian HH, Jr, Hoyer LW (1999) Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 81:240-244. (Pubitemid 29078310)
33. Chao H, Walsh CE (2001) Induction of tolerance to human factor VIII in mice. Blood 97:3311-3312.
34. Connelly S, et al. (1996) Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 88:3846-3853. (Pubitemid 26383107)
35. Sarkar R, Gao GP, Chirmule N, Tazelaar J, Kazazian HH, Jr. (2000) Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. HumGene Ther 11:881-894. (Pubitemid 30202479)
36. Morral N, et al. (1998) High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 9:2709-2716. (Pubitemid 29027014)
37. Morsy MA, et al. (1998) An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95:7866-7871. (Pubitemid 28326032)
38. Schiedner G, et al. (1998) Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 18:180-183. (Pubitemid 28082470)
39. Reddy PS, et al. (2002) Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 5:63-73. (Pubitemid 34110482)
40. Brunetti-Pierri N, et al. (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15:35-46. (Pubitemid 38147187)
41. Schnell MA, et al. (2001) Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 3:708-722. (Pubitemid 32509868)
42. Muruve DA, Barnes MJ, Stillman IE, Libermann TA (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10:965-976. (Pubitemid 29195426)
43. Yang Y, et al. (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407-4411. (Pubitemid 24143442)
44. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152-155.
45. Kraaijenhagen RA, et al. (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83:5-9. (Pubitemid 30045467)
46. Bank I, et al. (2007) Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study. Thromb Haemost 98:1040-1044. (Pubitemid 350091133)
47. Sarkar R, et al. (2004) Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103:1253-1260. (Pubitemid 38168635)
48. Garza KM, Agersborg SS, Baker E, Tung KS (2000) Persistence of physiological self antigen is required for the regulation of self tolerance. J Immunol 164:3982-3989.
49. Rocha B, Tanchot C, Von Boehmer H (1993) Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 177:1517-1521. (Pubitemid 23117145)
50. Triplett EL (1962) On the mechanism of immunologic self recognition. J Immunol 89:505-510.
51. Brunetti-Pierri N, et al. (2005) Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther 12:99-106. (Pubitemid 40862361)
52. Palmer D, Ng P (2003) Improved system for helper-dependent adenoviral vector production. Mol Ther 8:846-852. (Pubitemid 37527461)
53. Palmer DJ, Ng P (2004) Physical and infectious titers of helper-dependent adenoviral vectors: A method of direct comparison to the adenovirus reference material. Mol Ther 10:792-798. (Pubitemid 39272868)
54. Ng P, Parks RJ, Graham FL (2002) Preparation of helper-dependent adenoviral vectors. Methods Mol Med 69:371-388.
55. Bi L, et al. (1995) Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10:119-121.
56. Bi L, et al. (1996) Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 88:3446-3450. (Pubitemid 26365578)
57. Dejana E, Callioni A, Quintana A, de Gaetano G (1979) Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res 15:191-197.